Monograph Details
|
|
Dermatological Disorders
> Warts
|
|
ALDARA |
| Manufacturer |
|
Graceway Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Immune response modifier. |
| Generic Name |
|
Imiquimod 5%; crm. |
| Indications |
|
External genital warts. Perianal warts. |
| Children |
|
Not recommended. |
| Adults |
|
Apply thin layer to warts and rub in before bedtime 3 times per week; wash off with soap and water 6–10 hours later; max 16 weeks. Avoid sexual contact while cream is on skin. |
| Precautions |
|
Immunosuppressed. Not for use in treating urethral, intravaginal, cervical, rectal, or intra-anal warts. Not for use on unhealed lesions due to other therapies (drug or surgical). Do not occlude. Avoid eyes, lips, nostrils, sun or UV light exposure. May exacerbate inflammatory skin conditions. May suspend for several days if irritation occurs. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Concomitant use of diaphragms or condoms: not recommended. |
| Adverse Reactions |
|
Local and remote reactions (eg, erythema, erosion, excoriation, edema, itching, burning, soreness), headache, flu-like symptoms, myalgia, hypo- or hyperpigmentation. |
| How Supplied |
|
Single-use packets—12, 24 |
|
|
|
|
